Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”

SIMPLE SUMMARY: Patients with HER-2 positive breast cancer who progress through available HER2-targeted therapy, at present, have few effective treatment options. PIK3CA is mutated in approximately 20% of HER2 positive breast cancers, contributes to HER-2 therapy resistance and may be predictive of...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancers (Basel)
Main Authors: Keegan, Niamh M., Furney, Simon J., Walshe, Janice M., Gullo, Giuseppe, Kennedy, M. John, Smith, Diarmuid, McCaffrey, John, Kelly, Catherine M., Egan, Keith, Kerr, Jennifer, Given, Mark, O’Donovan, Peter, Hernando, Andres, Teiserskiene, Ausra, Parker, Imelda, Kay, Elaine, Farrelly, Angela, Carr, Aoife, Calzaferri, Giulio, McDermott, Ray, Keane, Maccon M., Grogan, Liam, Breathnach, Oscar, Morris, Patrick G., Toomey, Sinead, Hennessy, Bryan T.
פורמט: Artigo
שפה:Inglês
יצא לאור: MDPI 2021
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7999809/
https://ncbi.nlm.nih.gov/pubmed/33799597
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13061225
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים